These data are encouraging and support the hypothesis that development of centrally acting KMO inhibitors could be neuroprotective in AD since blocking microglial KYN metabolism would not only prevent production of neurotoxic metabolites such as 3-HK and Quin but also indirectly increase endogenously produced KYNA. The gene discussed is KMO; the disease is Alzheimer disease.